Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in Graves' disease 2
ISRCTN26277327Phase 3Recruiting
- Sponsor
- Newcastle Hospitals NHS Foundation Trust
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Graves' disease and hyperthyroidism comparing Standard ATD therapy + Placebo with Standard ATD therapy + Rituximab (2 arms). Primary endpoint: Primary remission endpoint. Started Jul 2025; status: recruiting.
02
Drugs
rituximab
03
Conditions
Graves' diseasehyperthyroidism
Beyond the preview
Go deeper on ISRCTN26277327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN26277327.